A Study of MabThera/Rituxan (Rituximab) in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's Lymphoma

Clinical Response in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's Lymphoma After Treatment With Anti-CD20 Antibody IDEC C2B8 (MabThera)

This study will evaluate the efficacy and safety of MabThera/Rituxan in patients with relapsed low-grade centroblastic centrocytic non-Hodgkin's lymphoma. Patients will receive once-weekly intravenous MabThera/Rituxan for 4 weeks; responding patients will be treated a second time in case of relapse (defined as progression after complete or partial response). The anticipated time on study treatment is <3 months.

Inclusion Criteria:

• adult patients >= 18 years of age;
• centrocytic centroblastic non-Hodgkin's lymphoma stage III-IV;
• relapse after chemotherapy (with or without interferon maintenance therapy).

Exclusion Criteria:

• primary refractory lymphomas;
• more than 3 relapses of centroblastic centrocytic non-Hodgkin's lymphoma;
• clinically significant cardiac disease.